S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Bank Accounts: Frozen! (Ad)
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
My No. 1 dividend stock for a LIFETIME of income. (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NASDAQ:GNCA

Genocea Biosciences - GNCA Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
6,414 shs
Average Volume
83,499 shs
Market Capitalization
$6,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

GNCA stock logo

About Genocea Biosciences (NASDAQ:GNCA) Stock

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

Receive GNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

GNCA Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
GNCAQ Genocea Biosciences, Inc.
Genocea Biosciences, Inc. (GNCA)
GRPN, GNCA and LAB among mid-day movers
Genocea Biosciences to shut down
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Genocea Closes Shop, Delists From NASDAQ
Genocea cuts two-thirds of staff, explores a sale
Genocea Biosciences to Host Investor Webinar
Genocea Biosciences: Q4 Earnings Snapshot
Genocea Provides Fourth Quarter 2021 Corporate Update
Genocea Biosciences Q4 2021 Earnings Preview
Genocea Biosciences Earnings Preview
See More Headlines
Receive GNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

GNCA Company Calendar

Last Earnings
10/27/2021
Today
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNCA
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-33,200,000.00
Pretax Margin
-1,946.15%

Debt

Sales & Book Value

Annual Sales
$1.91 million
Book Value
$0.47 per share

Miscellaneous

Free Float
57,788,000
Market Cap
$6,000.00
Optionable
Optionable
Beta
1.61

Key Executives

  • Mr. William D. Clark M.B.A. (Age 53)
    Pres, CEO & Director
    Comp: $837.42k
  • Dr. Jessica Baker Flechtner Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $585.18k
  • Ms. Diantha Duvall CPA (Age 50)
    M.B.A., CFO & Sec.













GNCA Stock - Frequently Asked Questions

Should I buy or sell Genocea Biosciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GNCA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNCA, but not buy additional shares or sell existing shares.
View GNCA analyst ratings
or view top-rated stocks.

What is Genocea Biosciences' stock price forecast for 2023?

2 analysts have issued 1-year price targets for Genocea Biosciences' stock. Their GNCA share price forecasts range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months.
View analysts price targets for GNCA
or view top-rated stocks among Wall Street analysts.

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter. During the same quarter last year, the firm posted ($0.26) earnings per share.

What is William Clark's approval rating as Genocea Biosciences' CEO?

5 employees have rated Genocea Biosciences Chief Executive Officer William Clark on Glassdoor.com. William Clark has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How do I buy shares of Genocea Biosciences?

Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Genocea Biosciences make?

Genocea Biosciences (NASDAQ:GNCA) has a market capitalization of $0.00 and generates $1.91 million in revenue each year. The biotechnology company earns $-33,200,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.genocea.com. The biotechnology company can be reached via phone at (617) 876-8191, via email at ir@genocea.com, or via fax at 617-876-8192.

This page (NASDAQ:GNCA) was last updated on 3/31/2023 by MarketBeat.com Staff